Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023
ASX:RCE
ASX:RCE
Recce Pharmaceuticals Ltd attracts $1.8 million as it moves toward human clinical trials Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors…
Recce Pharmaceuticals locks
Recce Pharmaceuticals locks
In US patent for synthetic antibiotic to target growing superbug problem Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the…
Director Trades
Director Trades
A millennial director put his $100k into his own company rather than a house deposit It was millionaire’s row last week in small cap land, with four multi-million dollar trades and one that was pretty close…
Health & Biotech
Health & Biotech
The biotech veteran chasing a billion-dollar pot of gold He was famously worth over $130 million — on paper at least — when he was running Chemeq, which blew itsel up a decade ago after he left.
Health & Biotech
Health & Biotech
Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having…
Sky Business News
Sky Business News
Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..
S&P Global
S&P Global
Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery…
The West Australian
The West Australian
WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started …